MA55766A - Nanoparticules lipidiques - Google Patents

Nanoparticules lipidiques

Info

Publication number
MA55766A
MA55766A MA055766A MA55766A MA55766A MA 55766 A MA55766 A MA 55766A MA 055766 A MA055766 A MA 055766A MA 55766 A MA55766 A MA 55766A MA 55766 A MA55766 A MA 55766A
Authority
MA
Morocco
Prior art keywords
lipid nanoparticles
nanoparticles
lipid
Prior art date
Application number
MA055766A
Other languages
English (en)
Inventor
James Heyes
Adam Judge
Kieu Mong Lam
Alan D Martin
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of MA55766A publication Critical patent/MA55766A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA055766A 2019-04-26 2020-04-24 Nanoparticules lipidiques MA55766A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839452P 2019-04-26 2019-04-26
US201962867098P 2019-06-26 2019-06-26

Publications (1)

Publication Number Publication Date
MA55766A true MA55766A (fr) 2022-03-02

Family

ID=72941858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055766A MA55766A (fr) 2019-04-26 2020-04-24 Nanoparticules lipidiques

Country Status (8)

Country Link
US (1) US20220168222A1 (fr)
EP (1) EP3959314A4 (fr)
JP (1) JP2022530018A (fr)
CN (1) CN114026233A (fr)
AU (1) AU2020262437A1 (fr)
CA (1) CA3137450A1 (fr)
MA (1) MA55766A (fr)
WO (1) WO2020219941A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119051A1 (fr) * 2018-11-09 2020-05-14 Arbutus Biopharma Corporation Lipides cationiques contenant du silicium
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
US12023376B1 (en) 2020-04-17 2024-07-02 Triad National Security, Llc Conserved region T cell vaccines for coronavirus and methods of use
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
EP4251170A1 (fr) 2020-11-25 2023-10-04 Akagera Medicines, Inc. Nanoparticules lipidiques utilisées pour l'administration d'acides nucléiques, et méthodes d'utilisation associées
US20240148663A1 (en) * 2020-12-18 2024-05-09 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
WO2022198229A1 (fr) * 2021-03-17 2022-09-22 Board Of Regents Of The University Of Nebraska Formulations de nanoparticules lipidiques et leurs méthodes d'utilisation
EP4323525A2 (fr) 2021-04-16 2024-02-21 Genentech, Inc. Ligands tlr7 optimisés et leurs utilisations
WO2023031392A2 (fr) 2021-09-03 2023-03-09 CureVac SE Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques comprenant de la phosphatidylsérine
KR20230061895A (ko) * 2021-10-29 2023-05-09 주식회사 아이큐어비앤피 지질 나노입자 및 세포 투과성을 갖는 신규 펩타이드의 복합체
WO2023216232A1 (fr) * 2022-05-13 2023-11-16 南方科技大学 Composé lipidique contenant une liaison disulfure et composition de celui-ci
WO2023218431A1 (fr) 2022-05-13 2023-11-16 BioNTech SE Compositions d'arn ciblant le vih
WO2023230098A1 (fr) 2022-05-23 2023-11-30 Logicbio Therapeutics, Inc. Compositions de thérapie génique et leurs procédés d'utilisation
WO2023230295A1 (fr) 2022-05-25 2023-11-30 BioNTech SE Compositions d'arn pour l'administration d'antigènes de la variole du singe et méthodes associées
WO2023230587A2 (fr) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et leurs procédés d'utilisation
WO2023232747A1 (fr) 2022-05-30 2023-12-07 BioNTech SE Complexes pour l'administration d'acides nucléiques
WO2024010330A1 (fr) * 2022-07-06 2024-01-11 Green Cross Corporation Nanoparticules lipidiques utilisant du cholestérol cationique pour une administration locale pour l'administration d'acide nucléique
WO2024026308A2 (fr) 2022-07-29 2024-02-01 Massachusetts Institute Of Technology COMPOSITIONS ET MÉTHODES POUR INHIBER L'EXPRESSION DU GÈNE DE LA PROTÉINE RÉGULATRICE DE SIGNAL ALPHA (SIRPα)
WO2024037577A1 (fr) * 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition de nanoparticules lipidiques
WO2024057237A1 (fr) 2022-09-16 2024-03-21 Pfizer Inc. Nanoparticules lipidiques
EP4342460A1 (fr) 2022-09-21 2024-03-27 NovoArc GmbH Nanoparticule lipidique avec charge d'acide nucléique
WO2024131810A1 (fr) * 2022-12-21 2024-06-27 Suzhou Abogen Biosciences Co., Ltd. Nanoparticules lipidiques comprenant des phospholipides modifiés par stérol
WO2024141955A1 (fr) 2022-12-28 2024-07-04 BioNTech SE Compositions d'arn ciblant le vih
EP4410316A1 (fr) * 2023-02-01 2024-08-07 4basebio UK Ltd Nanoparticules pour l'administration de charges d'acides nucléiques
WO2024167924A2 (fr) * 2023-02-06 2024-08-15 University Of Tennessee Research Foundation Nanoparticules lipidiques multifonctionnelles et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3386484T3 (pl) * 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
CN109563511A (zh) * 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法

Also Published As

Publication number Publication date
EP3959314A1 (fr) 2022-03-02
EP3959314A4 (fr) 2023-02-08
CN114026233A (zh) 2022-02-08
CA3137450A1 (fr) 2020-10-29
US20220168222A1 (en) 2022-06-02
AU2020262437A1 (en) 2021-12-23
JP2022530018A (ja) 2022-06-27
WO2020219941A1 (fr) 2020-10-29

Similar Documents

Publication Publication Date Title
MA55766A (fr) Nanoparticules lipidiques
IL282995A (en) Formulations of lipid nanoparticles
DK3515946T5 (da) Anti-MUC16-(MUCIN 16)-antistoffer
BR112017023853A2 (pt) composições de nanopartícula para terapia sustentada.
JP2016502162A5 (fr)
EP3662913A4 (fr) Nanoparticules lipidiques contenant un acide nucléique
DK3733641T3 (da) Kationiske lipider
JP2015520632A5 (fr)
MA46867A (fr) Formulations pharmaceutiques
DK3694568T3 (da) Amfifil antimikrobiel hydrogel
DK3662894T3 (da) Nanopartikler omfattende tacrolimus
DK3583934T3 (da) Biocidholdigt middel
MA43648A (fr) Conjugués de nanoparticules
ES2642175T3 (es) Cable
JP2015514574A5 (fr)
MA42048A (fr) Dérivés d'aminoesters
FR3008900B1 (fr) Nanoparticules lipidiques multicompartimentees
JP2016064626A5 (fr)
JP2014189771A5 (fr)
IT201700035964A1 (it) “divisorio per boiserie”
DE102017109101A8 (de) Wickelvorrichtung
JP2016222625A5 (fr)
DE112018001120A5 (de) Aufspulvorrichtung
DE112020001977A5 (de) Kugellager
UA40079S (uk) Коробочка